Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis

Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing–remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Andrew, de Seze, Jérôme, Comabella, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733135/
https://www.ncbi.nlm.nih.gov/pubmed/26758290
http://dx.doi.org/10.1007/s40263-015-0299-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733135/
https://www.ncbi.nlm.nih.gov/pubmed/26758290
http://dx.doi.org/10.1007/s40263-015-0299-y

Ejemplares similares